Using Cellex drug in patients with chronic ischemia of brain and moderate cognitive disorders
B.A. ABUSUEVA1, M.A. EVZELMAN2, P.R. KAMCHATNOV3, Kh.Ya. UMAROVA4
1Dagestan State Medical Academy, 1 Lenin Square, Makhachkala, Russian Federation, 367000
2 Medical Institute of Orel State University, 25 Oktyabrskaya Str., Orel, Russian Federation, 302028
3 Russian National Research Medical University named after N.I. Pirogov, 1 Ostrovityanova Str., Moscow, Russian Federation, 117997
4Chechen State University, 32 Sheripov Str., Grozny, Russian Federation, 364093
Abusueva B.A. ― Cand. Med. Sc., Associate Professor, Head of the Department of Nervous Diseases, Neurosurgery and Medical Genetics
Evzelman M.A. ― D. Med. Sc., Professor of the Department of Psychiatry and Neurology
Kamchatnov P.R. ― D. Med. Sc., Professor of the Department of Neurology, Neurosurgery and Medical Genetics
Umarova Kh.Ya. ― D. Med. Sc., Professor of the Department of Hospital Therapy with courses Outpatient Therapy, Propedeutics in Internal Diseases, general treatment of patients
Chronic ischemia of brain is a widely spread type of cerebral-vascular pathology, and its presence is connected with the increased risk of both the acute ischemic stroke and the lasting neurologic deficit, first of all, cognitive disorders. Correction of the factors of cardio-vascular risk can slow down the progress of vascular lesion of brain, while maintenance of cognitive functions requires other therapeutic approaches. The authors consider the possibilities of using the new Russian drug Cellex in patients with moderate cognitive disorders in chronic ischemia of brain.
Key words: chronic ischemia of brain, moderate cognitive disorders, therapy, Cellex.